Human epidermal growth factor receptor-2 and hormonal therapies: Clinical implications

Clinical Breast Cancer

Volumn 4, Issue SUPPL. 1, 2003, Pages

  Ring, Alistair ^a   Dowsett, Mitch ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitors; Estrogen; Tamoxifen; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; DROLOXIFENE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; FADROZOLE; FLUOROURACIL; FULVESTRANT; GOSERELIN; IDOXIFENE; LETROZOLE; MEGESTROL ACETATE; MEMBRANE RECEPTOR; METHOTREXATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG; VOROZOLE;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESPONSE; DRUG TARGETING; HUMAN; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT PLANNING;

EID: 0038445408     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.s.013     Document Type: Article

References (39)

1. Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13:513-529.
2. Ingle JN, Mailliard JA, Schaid DJ, et al. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer 1991; 68:34-39.
3. Paridaens R, Sylvester RJ, Ferrazzi E, et al. Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 1980; 46(suppl 12):2889-2895.
4. Campbell FC, Blamey RW, Elston CW, et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 1981; 2:1317-1319.
5. Lippman ME, Allegra JC. Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 1980; 46(suppl 12):2829-2834.
6. Stewart J, King R, Hayward J, et al. Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Res Treat 1982; 2:243-250.
7. Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351:1451-1467.
8. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20:1467-1472.
9. Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus. tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18:3471-3479.
10. Knoop AS, Bentzen SM, Nielsen MM, et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001; 19:3376-3384.
11. Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001; 19:329-335.
12. Dowsett M, Baum M, Salter J, et al. ER, PgR, c-ERBB2 and EGFR in patients randomised to adjuvant tamoxifen: combinations of biomarkers as discriminants of treatment benefit. Breast Cancer Res Treat 1999; 57:61 (Abstract #222).
13. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993; 24:85-95.
14. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10:2435-2446.
15. Kurokawa H, Lenferink AE, Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen- resistant breast cancer cells. Cancer Res 2000; 60:5887-5894.
16. Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 2001; 7(suppl 12):4429S-4435S.
17. Osborne CK, Schiff R, Fuqua SA, et al. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001; 7(suppl 12):4338S-4342S.
18. Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 2001; 7(suppl 12):4436S-4442S.
19. Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14:2702-2708.
20. De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN Randomized Trial: predictive factors of adjavant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003; 9:1039-1046.
21. Stal O, Borg A, Ferno M, et al. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 2000; 11:1545-1550.
22. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002; 20:3317-3327.
23. Houston SJ, Plunkett TA, Barnes DM, et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999; 79:1220-1226.
24. Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998; 4:7-12.
25. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15:2518-2525.
26. Nicholson RI, McClelland RA, Finlay P, et al. Relationship between EGFR, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 7:1018-1023.
27. Archer SG, Eliopoulos A, Spandidos D, et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995; 72:1259-1266.
28. Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-1135.
29. Berns EM, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995; 159:11-18.
30. Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65:118-121.
31. De Laurentiis M, Arpino G, Massarelli E, et al. A metaanalysis of the interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000; 19:78a (Abstract #300).
32. Makris A, Powles TJ, Allred DC, et al. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 1998; 48:11-20.
33. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001; 61:8452-8458.
34. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19:3808-3816.
35. McClelland RA, Barrow D, Madden TA, et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001; 142:2776-2788.
36. Nicholson RI, Hutcheson IR, Harper ME, et al. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen receptor-positive breast cancer. Endocr Relat Cancer 2001; 8:175-182.
37. Maasarweh S, Shou J, Mohsin SK, et al. Inhibition of epidermal growth factor/HER2 receptor signalling using ZD1839 ("Iressa") restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors. Proc Am Soc Clin Oncol 2002; 21:33a (Abstract #130).
38. Newby JC, Johnston SR, Smith IE, et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997; 3:1643-1651.
39. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002; 359:2131-2139.